Tuesday, October 31, 2017 4:02:50 PM
I noticed that this has already been posted, but I think it bears repeating.
Seems like a good idea to have the International Patent, with big cannabinoid players like GW in Great Britain, out there.
"Prodrug technology enables delivery of cannabinoids without psychoactivity for treatment of pediatric conditions
LOS ANGELES, CA – (October 16, 2017) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals.
The publication of the international patent filing is the first public disclosure of its full content, which includes 79 patent claims and almost 200 individual compounds. Novel cannabinoid prodrugs are described for the most common phytocannabinoids, THC, cannabidiol (CBD), and CBDV, as well as a variety of other phytocannabinoids and endocannabinoids. The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide. Coverage of any underlying patent claims would extend to 2035 in the United States, and may be subject to patent term extensions that would extend this patent protection. The full text may be accessed online: “https://patentscope.wipo.int/search/docservicepdf_pct/id00000037217335/PDOC/WO2017053574.pdf”.
In addition, the Company has filed for intellectual property coverage for methods to treat dysbiosis, gastrointestinal infections, and other digestive disorders using cannabinoids. The Company’s prodrug technology enables large concentrations of cannabinoids to be selectively delivered to the intestinal tract and avoids psychoactivity, making them well suited for treatment of pediatric conditions.
“The publication of our international PCT patent filing gives shareholders a way to appreciate the depth and rigor of our work on the development of cannabosides,” said Robert Brooke, CEO of Vitality Biopharma. “Intellectual property is at the core of nearly every successful biotechnology or drug development company, so we plan to prosecute these claims and to maximize our coverage both in the U.S. and abroad.”
http://vitality.bio/2017/10/vitality-biopharma-announces-publication-international-pct-patent-filing-cannabinoid-pharmaceuticals/
Recent RNGE News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 01:15:36 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 01:36:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:12:25 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/08/2024 06:54:30 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM